News

Based on the FDA feedback, the company will be moving into Phase II/III on one NDA Program, and into Phase II on the other. In line with the

Trial Interactive is a web-based, 21 CFR Part 11 compliant platform that combines clinical documentation and trial development. TransPerfect’s Life Sciences Solutions division is committed to the e-clinical

This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen’s intellectual property portfolio for pluripotent

David Sackler, Nutroganics’ President & CEO, said, "We are pleased to announce this first step in increasing the disclosure and transparency of the operations and performance of Nutroganics

The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the Company’s key technology platform, its method for 3-dimensional expansion of placental

Pristima is software as a service (SaaS) model that consolidates several systems and applications into a single, global solution. As part of the deal, Pfizer will implement a

Data from two clinical trials was presented at the American Diabetes Association 74th Scientific Sessions. In the two-year trial, empagliflozin in combination with certain other diabetes therapies showed

The company said that Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for sentinel lymph node detection and was first approved in March 2013 for lymphatic mapping

As part of the deal, the option to license extended to Celgene through the end of Phase I, but AG-221 has been exercised early based on the Phase